Management of dabigatran-induced bleeding: Expert statement

Wiener Klinische Wochenschrift

Volumn 125, Issue 21-22, 2013, Pages 721-729

  Fries, Dietmar ^a   Giurea, Alexander ^b   Gutl, Manfred ^c   Halbmayer, Walter Michael ^d   Kozek Langenecker, Sibylle ^e   Pachucki, Andreas ^f   Roithinger, Franz ^b   Steinlechner, Barbara ^b   Thaler, Heinrich ^g   Weltermann, Ansgar ^h  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Krankenhaus Hietzing   (Austria)

^e Evangelical Hospital Vienna   (Austria)

^f Landesklinikum Amstetten ^*  (Austria)

^g Trauma Hospital Meidling   (Austria)

^h ELISABETHINEN HOSPITAL   (Austria)

Author keywords

Ccarin clotting time; Haemodialysis; Patient blood management; Prothrombincomplex concentrate; Recombinant factor VIIa; Thrombin time

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIVITAMIN K; COFACT; DABIGATRAN; DABIGATRAN ETEXILATE; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ANALYTICAL EQUIPMENT; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPRESSION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; EMBOLISM; EMERGENCY CARE; ERYTHROCYTE TRANSFUSION; HEMOFILTRATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; RISK ASSESSMENT; SCLEROTHERAPY; SURGICAL TECHNIQUE; THROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTITHROMBINS; AUSTRIA; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MONITORING, INTRAOPERATIVE; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINES AS TOPIC; THROMBOSIS;

EID: 84890118936     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0430-3     Document Type: Article

References (35)

1. Fugate JE, Rabinstein AA, McBane RD, Lanzino G. Dabigatran: a primer for neurosurgeons. World Neurosurg. 2012 Jun 19. doi:pii:S1878-8750(12)00639-0. 10.1016/j.wneu.2012.06.019 (Epub ahead of print).
2. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, American college of chest physicians antithrombotic therapy and prevention of thrombosis panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):7S-47S.
3. Kozek-Langenecker S, Afshari S, Albaladejo P, Santullano CA, De Robertis E, Filipescu D, Fries D, Gorlinger K, Haas T, Imberger G, Jacob M, Lancé M, Llau J, Mallett S, Meier J, Rahe-Meyer N, Samama CM, Smith A, Solomon C, Van der Linden P, Wikkelsø A, Wouters P, Wyffels P. Guidelines on the management of severe perioperative bleeding. Eur J Anaesthesiol. 2013;30(6):270-382.
4. Weltermann A, Brodmann M, Domanovits H, Eber B, Gottsauner-Wolf M, Halbmayer WM, Hiesmayr JM, Kyrle PA, Langle F, Roithinger FX, Watzke H, Windhager R, Wolf C, Zweiker R. Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. Wien Klin Wochenschr. 2012;124(9-10):340-7.
5. Cheng JW, Vu H. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. Clin Ther. 2012;34(4):766-87.
6. Kreutz R. Pharmakologie neuer oraler Antikoagulantien. Grundlage fur rationale Entscheidungen. Klinikarzt. 2012;41(S1):10-5.
7. Spannagl M, Bauersachs E, Debus ES, Gawaz M, Gerlach H, Haas S, Hach-Wunderle V, Lindhoff-Last E, Riess H, Schellong S, Schinzel H, Bode C. Therapie mit Dabigatran - Periinterventionelles Management und Interpretation von Gerinnungstests. Hamostaseologie. 2012;32:294-305.
8. www.akdae.de; Leitfaden der Arzneimittelkommission der deutschen Arzteschaft. Orale Antikoagulation bei nicht valvularem Vorhofflimmern. Empfehlungen zum Einsatz der neuen Antikoagulantien Dabigatran (Pradaxa) und Rivaroxaban (Xarelto). Version 1.0, September 2012.
9. Samama CM. New anticoagulants: pharmacology and clinical studies. Wien Med Wochenschr. 2011;161(3-4):54-7.
10. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral 2 thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303.
11. Sauer H, Wankmuller H, Leschke M. Blutungsmanagement, perioperatives und periprozedurales Bridging: Vorschlag praktischer Strategien fur die neuen oralen Antikoagulantien. Klinikarzt. 2012;41:26-32.
12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
13. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbuchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, van Gelder IC, Verheugt FW. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-47.
14. Halbmayer WM, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med. 2012;50(9):1601-5. doi:10.1515/cclm-2011-0888.
15. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A, Expert group on coagulation of the external quality assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105(2):371-8.
16. Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of 2 oral anticoagulation. Results from the national multicentre BNK Online bridging registry (BORDER). Thromb Haemost. 2012;108(1):65-73.
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.
18. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-18.
19. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52.
20. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements 2 critical care. Transfusion requirements in critical care investigators, canadian critical care trials group. N Engl J Med. 1999;340(6):409-17.
21. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR, Task force for advanced bleeding care in trauma. Management of bleeding following major trauma: an updated European guideline. Crit Care. 2010;14(2):R52.
22. Fries D, Innerhofer P, Perger P, Gutl M, Hofmann N, Kneifel W, Neuner L, Pernerstorfer T, Pfanner G, Schochl H, Ziegler B, Kolblinger C, Kozek-Langenecker SA. Gerinnungsmanagement bei traumatisch bedingter Massivblutung. AINS. 2010;45:552-61.
23. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Eng J Med. 2011;365:2038-40.
24. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012;126(20):2428-32.
25. Pezborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats (Abstract). Pathophysiol Haemost Thromb. 2010;37:A10-OC251.
26. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate - a novel, reversible. oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-27.
27. Eerenberg ES. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation. 2011;124:1573-9.
28. Baron TH, Kamath PS, McBane RD. Management of anithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113-24.
29. Kozek-Langenecker S, Sorensen B, Hess J, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Critical Care. 2011;15:R239.
30. Abdel-Wahab O, Healy B, Dzik W. Effect of fresh frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006;46:1279-85.
31. Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Hematology Am Soc Hematol Educ Program. 2012;2012:529-35.
32. Goodnough LT, Shander A. Special article: current status of pharmacologic therapies. Anesth Analg. 2013;116:15-34.
33. Regionalanasthesie unter gerinnungshemmender Medikation. Empfehlungen der Arbeitsgruppe perioperative Gerinnung der OGARI. http://www.oegari.at/web- files/dateiarchiv/116/Regionalanasthesie%20und%20Gerinnungshemmer%202013.pdf. Last access 24 Sep 2013.
34. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau J, Samama M. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999-1015.
35. Afshari A, Wikkelsø A, Brok J, Møller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev. 2011;(3):CD007871. doi:10.1002/14651858.CD007871.